Aug 18 (Reuters) - Ceapro Inc CZO.V :
* CEAPRO INC. PROVIDES UPDATE ON DEVELOPMENT OF AN INHALABLE THERAPEUTIC FOR COVID-19
* CEAPRO - IN-VITRO STUDY WITH HUMAN CELL LINES SHOWED PGX-YBG OBTAINED FROM DIFFERENT SOURCES EXHIBITED SIGNIFICANT STIMULATORY EFFECT ON HUMAN IMMUNE RESPONSE
* CEAPRO INC - EXPECTS PGX-YBG WILL STIMULATE HUMAN IMMUNE RESPONSE ONCE INHALED INTO LUNGS & POTENTIALLY PREVENT REACTIONS LIKE CYTOKINE STORM
* CEAPRO INC - RESULTS DEMONSTRATED IN IN-VITRO STUDY WERE CONSISTENT WITH RESULTS SEEN IN PRELIMINARY BIOLOGICAL STUDY
* CEAPRO - PREPARATIONS OF A PHASE 1/2 CLINICAL TRIAL PROTOCOL TO BE COMMENCED IMMEDIATELY, PLANNED TO BE SUBMITTED TO HEALTH AUTHORITIES DURING Q4 2020
* CEAPRO - FIRST MILESTONE TO OPTIMIZE SIZE & MORPHOLOGY OF BEST PGX-YBG FOR IMMUNOMODULATION WAS FULLY ACHIEVED